New drug aims to slow kidney damage in patients with high uric acid

NCT ID NCT07323095

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new medicine called ABP-671 in 80 adults with chronic kidney disease and high uric acid levels. Participants will receive either the drug or a placebo for 40 weeks. The main goal is to see if the drug reduces protein in the urine, a sign of kidney damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC KIDNEY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tsinghua Changgung Hospital

    Beijing, Beijing Municipality, 100000, China

  • Genesis Research services

    Newcastle, New South Wales, 2019, Australia

  • Jiangsu Province Hospital

    Nanjing, Jiangsu, 210000, China

  • Paratus Clinical Research Brisbane

    Brisbane, Queensland, Australia

  • Peking University First Hospital

    Beijing, Beijing Municipality, 100000, China

  • Renal Research Gosford Pty Ltd

    Gosford, New South Wales, 2250, Australia

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, 200000, China

  • Sir Run Run Shaw Hospital , affiliated with the Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

  • Xuanwu Hospital Capital Medical University

    Beijing, Beijing Municipality, 100000, China

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.